Global High Flow Nasal Cannula Market Definition
High-flow nasal cannula (HFNC) oxygen therapy is a revolutionary innovation that delivers a high flow of heated and humidified gas using a nasal cannula. HFNC appears to be a promising alternative treatment for hypoxemic acute respiratory failure (ARF), since it is easier to use and apply than noninvasive ventilation (NIV). HFNC is supplemental oxygen for patients with respiratory illnesses and is not able to deoxygenate the gas in their blood.
Normal oxygen flow devices are limited to only 15 liters per minute, while HFNC delivers humidified and heated oxygen at a rate of 60 liters per minute. It reduces the respiratory rate of the patient, increases tidal, and end-expiratory volumes, and releases CO2 from the body. It helps to decrease nasopharyngeal airway resistance, that provides good ventilation and free oxygen with the use of positive end-expiratory pressure.
It is the first line of treatment in patients with suffering from oxygen deficiency. The application of HFNC is mainly included in disorders such as general respiratory failure, chronic obstructive pulmonary disease, bronchitis, pneumonia, congestive heart failure, exacerbations, and many more. HNFC is used in neonatal care where babies are born prematurely suffering from infant respiratory distress syndrome and are unable to breathe properly.
Global High Flow Nasal Cannula Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~12% |
|
Base Year Market Size (2022) |
~ USD 9 Billion |
|
Forecast Year Market Size (2033) |
~ USD 17 Billion |
|
Regional Scope |
|
Global High Flow Nasal Cannula Market Size, Forecast, and Trend Highlights Over 2023 - 2033
The global high flow nasal cannula market is estimated to garner a revenue of USD 17 Billion by the end of 2033 by growing at a CAGR of ~12% over the forecast period, i.e., 2023 – 2033. Further, the market produced a revenue of USD 9 Billion in the year 2022. The growth of the market is primarily attributed to the radically increasing cases of asthma along with chronic obstructive pulmonary diseases across the globe. As per the World Health Organization, globally, asthma is expected to have killed 455 000 people in 2019 and impacted 262 million people in the same year. Increasing air pollution is caused by the presence of particulate matter and ozone, and an increasing number of indoor air pollutants, which include tobacco smoke, dust mites, cockroaches, mold & pesticides. The pollution caused by fossil fuel combustion, the growing number of industries, transportation, and the rising use of chemicals across the world is estimated to propel the growth of the market.
Get more information on this report:Download Sample PDF
The nasal cannula is used in cases where people are not able to breathe or get sufficient oxygen for the proper functioning of the body. This is a common phenomenon among patients who are suffering from asthma, COPD, or any other respiratory illness. In addition to this, the market is estimated to grow on the basis of the rising prevalence of asthma and respiratory tract illnesses among children across the world. Also, asthma is the most common chronic condition affecting children as per the reports. As per the estimations, about 5.1 million asthmatic children are under the age of 18. Moreover, about, 11 Americans die from asthma every day, and asthma-related deaths reached to 4,145 in the year 2020. Besides this, the launch of novel advanced products by the key manufacturers is another major factor that is fueling the growth of the market over the projected period.
Global High Flow Nasal Cannula Market: Growth Drivers and Challenges
Growth Drivers
-
Rising Geriatric Population across the Globe with Reduced Immunity – In people 65 years of age or older, asthma is common. Asthma affects about 7.8% of older individuals in the US. Asthma and other respiratory illnesses are frequent and more common in elderly people. With aging, the immunity to fight back illness slows down and, with that, the geriatric population becomes more prone to chronic illness. Hence, the rising geriatric population and the increasing prevalence of asthma among the elderly are estimated to drive market growth.
-
Growing Investment in Research and Development Owing to Increasing Funds – According to data compiled by the World Bank, the global research and development expenditures made up 2.23% of GDP in 2018.
-
Increasing Spending on Healthcare with Rising Awareness of Health Among People – For instance, in the last 20 years, global health spending has increased overall and reached USD 8.5 trillion in 2019 with 9.8% of GDP, up from 8.5 percent in 2000.
- Rising Prevalence of Asthma with Rising Respiratory Diseases – The increasing demand for the chronic respiratory diseases treatment is expected to boost the market’s growth in the upcoming years. Over 20 million Americans above the age of 18 suffer from asthma, and adult females are more likely than adult males to be affected. Compared to 6.1 percent of adult males, it affects roughly 9.8 percent of adult females.
-
Growing Adoption of Ambulatory Surgeries Around the World – It was observed that over the past 25 years, the number of ambulatory surgeries performed at community hospitals in the United States has steadily increased, rising from 13.4 million in 1995 to 19.2 million in 2018.
Challenges
- Side Effects of Using High Flow Nasal Cannula – While using high flow nasal cannulas, unwarmed and dry gas is estimated to be harmful to people with respiratory failure. Breathing dry air produces excessive water loss by the nasal mucosa, which may limit the nasal mucociliary clearance rate through alterations in the rheological characteristics or adhesiveness of nasal mucus and/or ciliary pulse shortening. This factor is anticipated to hinder the growth of the market during the forecast period.
- Suitability Issues for Long-Term Usage
- High Cost of the Product in the Market
Market Segmentation
The global high flow nasal cannula market is segmented and analyzed for demand and supply by application into acute respiratory failure, chronic obstructive pulmonary disease (COPD), acute heart failure, and others. Among these segments, the COPD segment is estimated to garner the largest market share as per the market analysis. COPD is a common pulmonary disease that affects the lungs of the patient. Furthermore, the increasing number of COPD cases is owing to the growing occupational inhalation of chemicals or dust. In addition, long-term exposure to tobacco smoke, indoor air pollution from allergens including animal fur, plant pollen, cooking smoke from cow dung or wood, the presence of respiratory infections, and any genetic deficiency are estimated to cause COPD. Across the world, over 3.23 million people died from COPD in 2019, as per the World Health Organization. The treatment with the high flow oxygen via nasal cannula helps to reduce respiratory rate and supports COPD patients with acute hypercapnic respiratory illness. It improves gas exchange in the blood to purify deoxygenated blood. This increase in demand for high flow nasal cannula application in COPD patients is anticipated to surge the segment’s growth in the market.
The global high flow nasal cannula market is also segmented and analyzed for demand and supply by end-user into hospitals and clinics, ambulatory care centers, long-term care centers, and others. Out of these, the hospitals & clinics segment is estimated to gain the largest market share by the end of 2033 on the back of the requirement for high flow nasal cannulas in hospitals and clinics, which is based on usage for a predetermined number of patients. Moreover, the number of hospitals and surgeries is growing, thus increasing the usage of the nasal cannula in the hospital is further predicted to boost the segment’s growth in the market. Further, approximately 40 to 50 million major surgeries are performed in the USA every year, and about 20 million in Europe, out of 310 million surgeries across the world.
Our in-depth analysis of the global high flow nasal cannula market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By End-User |
|
Global High Flow Nasal Cannula Market Regional Synopsis
The Asia Pacific high flow nasal cannula market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the growing geriatric and pediatric population, along with the increasing prevalence of asthma in the region. By 2050, one in four individuals in the region of Asia Pacific is estimated to get older than 60, and the incidence of asthma in the elderly population is about 1.3 to 15.3% compared to 5 percent of adults in the region, as per the reports. Moreover, with the rising cases of chronic respiratory diseases, there is also a surge in the number of surgeries conducted in the region every year. Along with this, the growing healthcare infrastructure, and improving healthcare facilities in the region are estimated to drive market growth in the region during the forecast period. The increasing urbanization from growing industries releases harmful gases and chemicals into the environment. In addition, the increasing automobile industry is also estimated to rise air pollution owing to elevating vehicles on the road.
Top Featured Companies Dominating the Global High Flow Nasal Cannula Market
-
Armstrong Medical Ltd
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eakin Healthcare Group
- ResMed Corp.
- Teleflex Incorporated
- Vapotherm, Inc.
- Becton, Dickinson, and Company
- Smiths Group plc
- CU Medical Systems, Inc
- Flexicare Medical Limited
- TEIJIN LIMITED
